Trials / Withdrawn
WithdrawnNCT01130324
VIBATIV Pregnancy Registry
VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Cumberland Pharmaceuticals · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to VIBATIV at any time during pregnancy. There are no mandated physician visits for the registry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIBATIV | Observational |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2020-10-01
- Completion
- 2020-10-01
- First posted
- 2010-05-26
- Last updated
- 2020-10-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01130324. Inclusion in this directory is not an endorsement.